Johnson & Johnson reported that subcutaneous amivantamab, a dual EGFR and MET inhibitor, achieved a 42% overall response rate in patients with advanced head and neck squamous cell carcinoma previously treated with immunotherapy and chemotherapy. More than one-third of responders had complete responses, and the median duration of response was not yet reached after nearly a year of follow-up. These promising results from the Phase 1b/2 OrigAMI-4 study highlight amivantamab's potential to improve outcomes in a cancer type with limited treatment options and poor prognosis. Johnson & Johnson has submitted a supplemental application to the FDA seeking approval for this indication, with further studies ongoing.
Johnson & Johnson's Phase 3 PROTEUS study shows ERLEADA (apalutamide) combined with hormone therapy before and after surgery significantly improves outcomes for high-risk localized prostate cancer patients. The treatment increased the chance of minim...
Johnson & Johnson's Phase 3 PROTEUS study found that combining apalutamide with hormone therapy before and after prostate cancer surgery significantly improves outcomes for high-risk localized or locally advanced prostate cancer patients. The treatme...
Johnson & Johnson announced that their drug combination RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) achieved a median overall survival of nearly 3.5 years in patients with advanced non-small cell lung cancer (NSCLC) harboring atypical EGF...
Johnson & Johnson announced positive Phase 3 results from the MajesTEC-9 study, showing TECVAYLI (teclistamab-cqyv) significantly improves progression-free and overall survival in relapsed or refractory multiple myeloma patients treated as early as s...
Johnson & Johnson announced FDA approval for an updated label on TREMFYA (guselkumab), highlighting its ability to inhibit structural joint damage progression in adults with active psoriatic arthritis (PsA). This update is based on positive 24-week P...
